Le Lézard
Classified in: Health, Covid-19 virus
Subject: DEI

PROJECT ON FAIR REPRESENTATION WARNS NEW YORK DEPARTMENT OF HEALTH ABOUT RACIALLY DISCRIMINATORY PRIORITIZATION OF COVID-19 TREATMENTS


AUSTIN, Texas, Jan. 19, 2022 /PRNewswire/ -- Late yesterday, the Project on Fair Representation sent a letter to New York Department of Health Acting Commissioner Mary T. Basset warning the Department about serious legal problems in the Department's new racially discriminatory guidance on the prioritization of COVID-19 treatments.

The letter notes that the Department's policy already has resulted in a lawsuit and warns the State will surely be sued again if it continues to prioritize treatments for certain racial and ethnic groups over others.

Specifically, the letter notes that, according to the Department's December 29th guidance, "Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from COVID-19."

Edward Blum, president of the Project on Fair Representation said, "if permitted to continue, this policy will lead to needless loss of life and will illegally perpetuate immoral racial categories."

Michael Buschbacher, an attorney at Boyden Gray & Associates said, "New York's racially discriminatory treatment plan reads like something from the pages of a 1920s racialist newsletter claiming that 'whites' are somehow inherently more resistant to disease than members of other races. This pseudo-scientific claptrap is wrong and immoral. The shortage of COVID-19 therapeutics is bad enough?New Yorkers of all races deserve better than having these lifesaving treatments rationed based on the color of their skin."

Contact: Edward Blum
703-505-1922
[email protected]

SOURCE Alliance for Fair Board Recruitment


These press releases may also interest you

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 08:00
Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami, sponsored by PrecisCa and the Community Oncology Alliance...

at 08:00
Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced its participation at two prestigious medical conferences: the American...



News published on and distributed by: